AVN 59.85 Decreased By ▼ -0.07 (-0.12%)
BOP 10.02 Decreased By ▼ -0.13 (-1.28%)
CHCC 131.99 Increased By ▲ 2.74 (2.12%)
DCL 9.19 Decreased By ▼ -0.17 (-1.82%)
DGKC 105.00 Decreased By ▼ -2.39 (-2.23%)
EFERT 66.37 Decreased By ▼ -1.32 (-1.95%)
EPCL 31.71 Decreased By ▼ -1.19 (-3.62%)
FCCL 20.59 Decreased By ▼ -0.16 (-0.77%)
FFL 13.21 Increased By ▲ 0.21 (1.62%)
HASCOL 16.38 No Change ▼ 0.00 (0%)
HBL 128.00 Decreased By ▼ -1.44 (-1.11%)
HUBC 89.54 Increased By ▲ 0.86 (0.97%)
HUMNL 8.97 Decreased By ▼ -0.03 (-0.33%)
JSCL 16.35 Decreased By ▼ -0.37 (-2.21%)
KAPCO 28.51 Increased By ▲ 0.09 (0.32%)
KEL 3.81 Decreased By ▼ -0.03 (-0.78%)
LOTCHEM 12.93 Decreased By ▼ -0.17 (-1.3%)
MLCF 35.22 Decreased By ▼ -0.65 (-1.81%)
OGDC 116.01 Increased By ▲ 1.11 (0.97%)
PAEL 34.11 Decreased By ▼ -0.61 (-1.76%)
PIBTL 11.81 Decreased By ▼ -0.19 (-1.58%)
PIOC 93.33 Increased By ▲ 2.13 (2.34%)
POWER 8.56 Decreased By ▼ -0.05 (-0.58%)
PPL 103.32 Increased By ▲ 0.18 (0.17%)
PSO 185.00 Decreased By ▼ -0.98 (-0.53%)
SNGP 58.73 Increased By ▲ 1.40 (2.44%)
STPL 11.70 Decreased By ▼ -0.10 (-0.85%)
TRG 50.53 Increased By ▲ 0.47 (0.94%)
UNITY 13.71 Increased By ▲ 0.74 (5.71%)
WTL 1.21 Decreased By ▼ -0.02 (-1.63%)
BR100 4,216 Decreased By ▼ -6 (-0.15%)
BR30 21,902 Increased By ▲ 159 (0.73%)
KSE100 40,291 Decreased By ▼ -182 (-0.45%)
KSE30 17,538 Decreased By ▼ -87 (-0.5%)
COVID-19 TOTAL DAILY
CASES 286,674 753
DEATHS 6,139 10
Sindh 124,929 Cases
Punjab 94,865 Cases
Balochistan 12,044 Cases
Islamabad 15,323 Cases
KP 34,947 Cases

(Karachi) Coronavirus vaccine candidates will enter late-stage clinical studies by the end of the month, with others beginning in August, September and October, the U.S. government’s top infectious diseases expert said on Thursday.

The news comes as Moderna Inc, which is at the forefront of the country’s vaccine development efforts, reiterated earlier in the day that a late-stage trial with 30,000 volunteers would begin this month.

World's first inactivated Covid-19 vaccine produces antibodies: Chinese experts

“We may be able to at least know whether we are dealing with a safe and effective vaccine by the early winter, late winter, (or) beginning of 2021,” Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases, said in an interview to JAMA Network.

According to the firm, volunteers who have undergone the phase II trial in May have shown positive early results, developing antibodies against the virus.

AstraZeneca, Moderna ahead in COVID-19 vaccine race: WHO

In June, China National Biotec Group (CNBG) announced that their inactivated COVID-19 vaccine had passed phase one and two clinical trials.

The vaccine showed no "serious adverse reactions" with all volunteers generating antibodies after two doses in 28 days, the company said.